Loading…
Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML
Micro-Abstract The incidence of acute myeloid leukemia (AML) increases with age, with poor prognosis in older patients. We report findings from a dose-escalation study of barasertib, an Aurora B kinase inhibitor, plus low-dose cytosine arabinoside (LDAC) in 22 AML patients aged 60 years or older. Th...
Saved in:
| Published in: | Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2013-10, Vol.13 (5), p.559-567 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c510t-d25e8c96d92f6c67e5c62540f0a6d55897d4e87410b9240518debc7b2439543e3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c510t-d25e8c96d92f6c67e5c62540f0a6d55897d4e87410b9240518debc7b2439543e3 |
| container_end_page | 567 |
| container_issue | 5 |
| container_start_page | 559 |
| container_title | Clinical lymphoma, myeloma and leukemia |
| container_volume | 13 |
| creator | Kantarjian, Hagop M Sekeres, Mikkael A Ribrag, Vincent Rousselot, Philippe Garcia-Manero, Guillermo Jabbour, Elias J Owen, Kate Stockman, Paul K Oliver, Stuart D |
| description | Micro-Abstract The incidence of acute myeloid leukemia (AML) increases with age, with poor prognosis in older patients. We report findings from a dose-escalation study of barasertib, an Aurora B kinase inhibitor, plus low-dose cytosine arabinoside (LDAC) in 22 AML patients aged 60 years or older. The maximum tolerated dose (MTD) of barasertib was 1000 mg. A preliminary overall response rate of 45% was reported. |
| doi_str_mv | 10.1016/j.clml.2013.03.019 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3775947</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S2152265013001213</els_id><sourcerecordid>23763917</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-d25e8c96d92f6c67e5c62540f0a6d55897d4e87410b9240518debc7b2439543e3</originalsourceid><addsrcrecordid>eNp9kt9qFDEUxgdRbK2-gBeSS73YNX8mkw1IYdxWLaxY2IrgTcgkZ7pZs5OSZCvzDL60GVYX9UI4kJCc33eS852qek7wnGDSvN7Ojd_5OcWEzXEJIh9Up5RwOqNNIx8e9xyfVE9S2mIscEl6XJ1QJhomiTitflxvdAJ0hdZ5b0fUpgQpueEW5Q2gte4hj0gPFt0ED1F3zrtyEHr0VsfCxew69LL9ekFKpVfoi8sbtArfZxehaC7HHIoUoHYCh7K3gNyALr2F6Ed0rbODIacD1n5cPa0e9donePZrPas-v7u8WX6YrT69v1q2q5nhBOeZpRwWRjZW0r4xjQBuGspr3GPdWM4XUtgaFqImuJO0xpwsLHRGdLRmktcM2Fl1ftC923c7sKY8Imqv7qLb6TiqoJ36-2ZwG3Ub7hUTgstaFAF6EDAxpBShP7IEq8katVWTNWqyRuESRBboxZ9Vj8hvL0rCm0MClL_fO4gqmdIgA9ZFMFnZ4P6vf_4PbrwbnNH-G4yQtmEfh9JVRVSiCqv1NBzTbBBWhoISxn4Cnhm1Dw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML</title><source>ScienceDirect Freedom Collection</source><creator>Kantarjian, Hagop M ; Sekeres, Mikkael A ; Ribrag, Vincent ; Rousselot, Philippe ; Garcia-Manero, Guillermo ; Jabbour, Elias J ; Owen, Kate ; Stockman, Paul K ; Oliver, Stuart D</creator><creatorcontrib>Kantarjian, Hagop M ; Sekeres, Mikkael A ; Ribrag, Vincent ; Rousselot, Philippe ; Garcia-Manero, Guillermo ; Jabbour, Elias J ; Owen, Kate ; Stockman, Paul K ; Oliver, Stuart D</creatorcontrib><description>Micro-Abstract The incidence of acute myeloid leukemia (AML) increases with age, with poor prognosis in older patients. We report findings from a dose-escalation study of barasertib, an Aurora B kinase inhibitor, plus low-dose cytosine arabinoside (LDAC) in 22 AML patients aged 60 years or older. The maximum tolerated dose (MTD) of barasertib was 1000 mg. A preliminary overall response rate of 45% was reported.</description><identifier>ISSN: 2152-2650</identifier><identifier>EISSN: 2152-2669</identifier><identifier>DOI: 10.1016/j.clml.2013.03.019</identifier><identifier>PMID: 23763917</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acute myeloid leukemia ; Age Factors ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Barasertib-hQPA ; Cytarabine - administration & dosage ; Cytarabine - pharmacokinetics ; Dose-escalation study ; Female ; Hematology, Oncology and Palliative Medicine ; Humans ; Leukemia, Myeloid, Acute - drug therapy ; Male ; Middle Aged ; Organophosphates - administration & dosage ; Organophosphates - pharmacokinetics ; Quinazolines - administration & dosage ; Quinazolines - pharmacokinetics ; Treatment Outcome</subject><ispartof>Clinical lymphoma, myeloma and leukemia, 2013-10, Vol.13 (5), p.559-567</ispartof><rights>Elsevier Inc.</rights><rights>2013 Elsevier Inc.</rights><rights>Copyright © 2013 Elsevier Inc. All rights reserved.</rights><rights>2013 Elsevier Inc. All rights reserved. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-d25e8c96d92f6c67e5c62540f0a6d55897d4e87410b9240518debc7b2439543e3</citedby><cites>FETCH-LOGICAL-c510t-d25e8c96d92f6c67e5c62540f0a6d55897d4e87410b9240518debc7b2439543e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,778,782,883,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23763917$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kantarjian, Hagop M</creatorcontrib><creatorcontrib>Sekeres, Mikkael A</creatorcontrib><creatorcontrib>Ribrag, Vincent</creatorcontrib><creatorcontrib>Rousselot, Philippe</creatorcontrib><creatorcontrib>Garcia-Manero, Guillermo</creatorcontrib><creatorcontrib>Jabbour, Elias J</creatorcontrib><creatorcontrib>Owen, Kate</creatorcontrib><creatorcontrib>Stockman, Paul K</creatorcontrib><creatorcontrib>Oliver, Stuart D</creatorcontrib><title>Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML</title><title>Clinical lymphoma, myeloma and leukemia</title><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><description>Micro-Abstract The incidence of acute myeloid leukemia (AML) increases with age, with poor prognosis in older patients. We report findings from a dose-escalation study of barasertib, an Aurora B kinase inhibitor, plus low-dose cytosine arabinoside (LDAC) in 22 AML patients aged 60 years or older. The maximum tolerated dose (MTD) of barasertib was 1000 mg. A preliminary overall response rate of 45% was reported.</description><subject>Acute myeloid leukemia</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Barasertib-hQPA</subject><subject>Cytarabine - administration & dosage</subject><subject>Cytarabine - pharmacokinetics</subject><subject>Dose-escalation study</subject><subject>Female</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Organophosphates - administration & dosage</subject><subject>Organophosphates - pharmacokinetics</subject><subject>Quinazolines - administration & dosage</subject><subject>Quinazolines - pharmacokinetics</subject><subject>Treatment Outcome</subject><issn>2152-2650</issn><issn>2152-2669</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kt9qFDEUxgdRbK2-gBeSS73YNX8mkw1IYdxWLaxY2IrgTcgkZ7pZs5OSZCvzDL60GVYX9UI4kJCc33eS852qek7wnGDSvN7Ojd_5OcWEzXEJIh9Up5RwOqNNIx8e9xyfVE9S2mIscEl6XJ1QJhomiTitflxvdAJ0hdZ5b0fUpgQpueEW5Q2gte4hj0gPFt0ED1F3zrtyEHr0VsfCxew69LL9ekFKpVfoi8sbtArfZxehaC7HHIoUoHYCh7K3gNyALr2F6Ed0rbODIacD1n5cPa0e9donePZrPas-v7u8WX6YrT69v1q2q5nhBOeZpRwWRjZW0r4xjQBuGspr3GPdWM4XUtgaFqImuJO0xpwsLHRGdLRmktcM2Fl1ftC923c7sKY8Imqv7qLb6TiqoJ36-2ZwG3Ub7hUTgstaFAF6EDAxpBShP7IEq8katVWTNWqyRuESRBboxZ9Vj8hvL0rCm0MClL_fO4gqmdIgA9ZFMFnZ4P6vf_4PbrwbnNH-G4yQtmEfh9JVRVSiCqv1NBzTbBBWhoISxn4Cnhm1Dw</recordid><startdate>20131001</startdate><enddate>20131001</enddate><creator>Kantarjian, Hagop M</creator><creator>Sekeres, Mikkael A</creator><creator>Ribrag, Vincent</creator><creator>Rousselot, Philippe</creator><creator>Garcia-Manero, Guillermo</creator><creator>Jabbour, Elias J</creator><creator>Owen, Kate</creator><creator>Stockman, Paul K</creator><creator>Oliver, Stuart D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20131001</creationdate><title>Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML</title><author>Kantarjian, Hagop M ; Sekeres, Mikkael A ; Ribrag, Vincent ; Rousselot, Philippe ; Garcia-Manero, Guillermo ; Jabbour, Elias J ; Owen, Kate ; Stockman, Paul K ; Oliver, Stuart D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-d25e8c96d92f6c67e5c62540f0a6d55897d4e87410b9240518debc7b2439543e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Acute myeloid leukemia</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Barasertib-hQPA</topic><topic>Cytarabine - administration & dosage</topic><topic>Cytarabine - pharmacokinetics</topic><topic>Dose-escalation study</topic><topic>Female</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Organophosphates - administration & dosage</topic><topic>Organophosphates - pharmacokinetics</topic><topic>Quinazolines - administration & dosage</topic><topic>Quinazolines - pharmacokinetics</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kantarjian, Hagop M</creatorcontrib><creatorcontrib>Sekeres, Mikkael A</creatorcontrib><creatorcontrib>Ribrag, Vincent</creatorcontrib><creatorcontrib>Rousselot, Philippe</creatorcontrib><creatorcontrib>Garcia-Manero, Guillermo</creatorcontrib><creatorcontrib>Jabbour, Elias J</creatorcontrib><creatorcontrib>Owen, Kate</creatorcontrib><creatorcontrib>Stockman, Paul K</creatorcontrib><creatorcontrib>Oliver, Stuart D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kantarjian, Hagop M</au><au>Sekeres, Mikkael A</au><au>Ribrag, Vincent</au><au>Rousselot, Philippe</au><au>Garcia-Manero, Guillermo</au><au>Jabbour, Elias J</au><au>Owen, Kate</au><au>Stockman, Paul K</au><au>Oliver, Stuart D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML</atitle><jtitle>Clinical lymphoma, myeloma and leukemia</jtitle><addtitle>Clin Lymphoma Myeloma Leuk</addtitle><date>2013-10-01</date><risdate>2013</risdate><volume>13</volume><issue>5</issue><spage>559</spage><epage>567</epage><pages>559-567</pages><issn>2152-2650</issn><eissn>2152-2669</eissn><abstract>Micro-Abstract The incidence of acute myeloid leukemia (AML) increases with age, with poor prognosis in older patients. We report findings from a dose-escalation study of barasertib, an Aurora B kinase inhibitor, plus low-dose cytosine arabinoside (LDAC) in 22 AML patients aged 60 years or older. The maximum tolerated dose (MTD) of barasertib was 1000 mg. A preliminary overall response rate of 45% was reported.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>23763917</pmid><doi>10.1016/j.clml.2013.03.019</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2152-2650 |
| ispartof | Clinical lymphoma, myeloma and leukemia, 2013-10, Vol.13 (5), p.559-567 |
| issn | 2152-2650 2152-2669 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3775947 |
| source | ScienceDirect Freedom Collection |
| subjects | Acute myeloid leukemia Age Factors Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Barasertib-hQPA Cytarabine - administration & dosage Cytarabine - pharmacokinetics Dose-escalation study Female Hematology, Oncology and Palliative Medicine Humans Leukemia, Myeloid, Acute - drug therapy Male Middle Aged Organophosphates - administration & dosage Organophosphates - pharmacokinetics Quinazolines - administration & dosage Quinazolines - pharmacokinetics Treatment Outcome |
| title | Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly Patients With AML |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T09%3A16%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20I%20Study%20Assessing%20the%20Safety%20and%20Tolerability%20of%20Barasertib%20(AZD1152)%20With%20Low-Dose%20Cytosine%20Arabinoside%20in%20Elderly%20Patients%20With%20AML&rft.jtitle=Clinical%20lymphoma,%20myeloma%20and%20leukemia&rft.au=Kantarjian,%20Hagop%20M&rft.date=2013-10-01&rft.volume=13&rft.issue=5&rft.spage=559&rft.epage=567&rft.pages=559-567&rft.issn=2152-2650&rft.eissn=2152-2669&rft_id=info:doi/10.1016/j.clml.2013.03.019&rft_dat=%3Cpubmed_cross%3E23763917%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c510t-d25e8c96d92f6c67e5c62540f0a6d55897d4e87410b9240518debc7b2439543e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/23763917&rfr_iscdi=true |